Comirnaty

Pfizer and BioNTech Report Promising Results for mRNA-Based Combination Vaccine Against Influenza and COVID-19

(IN BRIEF) Pfizer and BioNTech have announced positive topline results from a Phase 1/2 study of their mRNA-based combination vaccine…

7 months ago

EMA Recommends Pfizer and BioNTech’s Omicron XBB.1.5-Adapted COVID-19 Vaccine for Approval

(IN BRIEF) Pfizer and BioNTech have received a recommendation for marketing authorization from the European Medicines Agency's Committee for Medicinal…

8 months ago

EMA Backs Comirnaty Omicron XBB.1.5 Vaccine for Varied Ages Amid Variant Concerns

(IN BRIEF) EMA proposes Comirnaty Omicron XBB.1.5 vaccine for ages 6 months+, tailored to combat Omicron XBB.1.5 variant. One dose…

8 months ago